Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2017
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 07 Nov 2017 Planned End Date changed from 27 Oct 2017 to 28 Mar 2018.
- 20 Sep 2017 New trial record
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.